



Simplify SARS-CoV-2 testing

The BD Veritor™ Plus System

Rapid, reliable SARS-CoV-2 testing at the point of care

The portable, easy-to-use BD Veritor™ Plus System provides reliable SARS-CoV-2 results in 15 minutes

This product is only to be used under an Emergency Use Authorization



Be ready for SARS-CoV-2 testing

When your patients are in need of fast, reliable SARS-CoV-2 testing, turn to the BD Veritor™ Plus System. Offering lab-quality results at the point of care, in a simple-to-operate, handheld instrument.



Simplify the testing process

- Easy operation and 1-button functionality may potentially reduce manual test processing errors
- Enables intuitive sample processing with prefilled, unitized tubes color-coded by reagent or assay type



Achieve fast, reliable results

- Displays easy-to-read digital results for SARS-CoV-2 in 15 minutes
- Records results on secured drive
- Advanced particle technology enhances sensitivity by using a proprietary process to produce highly stable, modified colloidal metal particles, helping improve test performance*
- Adaptive read technology helps improve specificity to reduce false-positive results by compensating for background and nonspecific binding



Provide workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
 - **Walk away:** Test device is inserted immediately into Analyzer, enabling staff to multitask while sample incubates
 - **Analyze now:** Test device is inserted after incubation time is complete, allowing batches of samples to be tested



Provide result traceability

- Download and display LOT number, Patient/specimen ID, Operator ID and test records with BD Veritor™ InfoScan module
- Offers result-printing capabilities via USB port

*in comparison to visually read tests

1. BD Veritor System for Rapid Detection of SARS-CoV-2 package insert. Franklin Lakes, NJ: Becton, Dickinson and Company.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA
800.638.8663

bd.com/COVID-19

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2020 BD. All rights reserved. 469-WW-0420 July 2020

Clinical Performance¹

| PPA | NPA |
|-----------------------|-----------------------|
| 84% | 100% |
| (95% C.I. 67%–93%) | (95% C.I. 98–100%) |



Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

| Ordering information | Cat. no. | Qty. |
|--|----------|----------|
| BD Veritor™ System for Rapid Detection of SARS-CoV-2 | 256082 | 30 tests |
| Other BD Veritor™ related products | | |
| BD Veritor™ System Flu A+B Moderately complex | 256041 | 30 tests |
| BD Veritor™ System Flu A+B CLIA-waived kit | 256045 | 30 tests |
| BD Veritor™ System RSV CLIA-waived kit | 256038 | 30 tests |
| BD Veritor™ System RSV Moderately complex | 256042 | 30 tests |
| BD Veritor™ System Group A Strep CLIA-waived kit | 256040 | 30 tests |
| BD Veritor™ Plus System Analyzer | 256066 | 1 |
| BD Veritor™ InfoScan module 1 | 256068 | 1 |
| USB printer cable 1 | 443907 | 1 |

